PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR
Luděk Pour(University Hospital Brno), Enrique M. Ocio(Universidad de Salamanca), María‐Victoria Mateos(Hospital Clínico San Carlos), Vincent Ribrag(Institut Gustave Roussy), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Katell Le Dû(Clinique Victor Hugo), Paul G. Richardson(Harvard University), Lionel Karlin(Hôpital Lyon Sud), J. Delaunay(Université Paris-Sud), Albert Oriol(Institut Català d'Oncologia), Miguel Granell(Hospital de Sant Pau), Yvonne A. Efebera(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Vladimír Maisnar(Charles University), Roman Hájek(University Hospital Ostrava), Catriona Byrne(Oncopeptides (Sweden)), Jean‐Richard Eveillard(Centre Hospitalier Régional Universitaire de Brest), Christian Jacques(Bibliothèque et Archives nationales du Québec), Malin Sydvander(University Hospital Brno), Jan Štraub(University Hospital Brno), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 1
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k